Please wait



Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox not checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)


SCHEDULE 13D/A 0001654954-24-011641 0002036516 XXXXXXXX LIVE 2 Common Stock, $0.0001 Par Value 12/31/2024 false 0001716621 74933X609 Catheter Precision, Inc. 1670 HIGHWAY 160 WEST 1670 HIGHWAY 160 WEST FORT MILL SC 29708 B. Joseph Alley, Jr. 404-473-8500 Arnall Golden Gregory 171 17th Street NW, Suite 2100 Atlanta GA 30363 0002036516 N Jenkins Casey A. a OO N X1 155883.00 676360.00 155883.00 676360.00 832243.00 N 9.9 IN * With respect to Casey A. Jenkins, includes 150,000 shares subject to currently exercisable Series J Warrants. Does not include 262.256 shares of Series X Preferred Stock which are convertible into approximately 26,225 shares of common stock upon satisfaction of certain conditions that have not currently been met. ** With respect to the Jenkins Family Charitable Institute, includes 176,134 shares subject to currently exercisable Series H Warrants held by the Jenkins Family Charitable Institute. Does not include Series H, I and J Warrants held by the Jenkins Family Charitable Institute to purchase an aggregate of 873,866 shares of common stock which are currently not exercisable due to beneficial ownership blockers. Does not include 18.691 shares of Series X Preferred Stock held by the Jenkins Family Charitable Institute which are convertible into approximately 1,869 shares of common stock upon satisfaction of certain conditions that have not currently been met. *** Based on 8,004,633 shares of common stock outstanding on December 31, 2024. 0002036806 N Jenkins Family Charitable Institute a OO N LA 676360.00 0.00 676360.00 0.00 676360.00 N 8.3 OO * Includes 176,134 shares subject to currently exercisable Series H Warrants held by the Jenkins Family Charitable Institute. Does not include Series H, I and J Warrants held by the Jenkins Family Charitable Institute to purchase an aggregate of 873,866 shares of common stock which are currently not exercisable due to beneficial ownership blockers. Does not include 18.691 shares of Series X Preferred Stock held by the Jenkins Family Charitable Institute which are convertible into approximately 1,869 shares of common stock upon satisfaction of certain conditions that have not currently been met. ** Based on 8,004,633 shares of common stock outstanding on December 31, 2024. Common Stock, $0.0001 Par Value Catheter Precision, Inc. 1670 HIGHWAY 160 WEST 1670 HIGHWAY 160 WEST FORT MILL SC 29708 1670 HIGHWAY 160 WEST, SUITE 205, FORT MILL, SOUTH CAROLINA , 29708. 1. Casey A. Jenkins is a reporting person filing this statement and is the trustee of the Jenkins Family Charitable Institute, which is a reporting person filing this statement. Her address is 225 Franz Valley School Road, Calistoga, CA 94515. 2. The Jenkins Family Charitable Institute is a reporting person filing this statement. It is a private foundation, and its principal business address is 225 Franz Valley School Road, Calistoga, CA 94515. See (a) above. Ms. Jenkins is the Vineyard Manager for Heritage School Vineyards, LLC. The Jenkins Family Institute's principal business is to serve as a family charitable entity. None. None. United States Approximately $500,000 of funds held by the Jenkins Family Charitable Institute (the "Institute") were used to purchase 265,000 common stock units and 235,000 pre-funded units of the Company in an underwritten public offering (the "Public Offering") pursuant to an underwriting agreement dated August 30, 2024. Each common stock unit, priced at a public offering price of $1.00 per unit, consisted of one share of common stock, one warrant to purchase one share of common stock at an exercise price of $1.00 per share that expires on the six month anniversary of the date of issuance (a "Series H Warrant"), one warrant to purchase one share of common stock at an exercise price of $1.00 per share that expires on the eighteen month anniversary of the date of issuance (a "Series I Warrant"), and one warrant to purchase one share of common stock at an exercise price of $1.00 per share that expires on the five year anniversary of the date of issuance (a "Series J Warrant"). Each pre-funded unit, priced at a public offering price of $0.9999 per unit, consisted of one pre-funded warrant to purchase one share of common stock at an exercise price of $0.0001 per share that has no expiration date (a "Pre-Funded Warrant" and together with the Series H Warrants, Series I Warrants and Series J Warrants, the "Warrants"), one Series H Warrant, one Series I Warrant and one Series J Warrant. The Public Offering closed on September 3, 2024. Each of the Warrants contained a beneficial ownership blocker that currently prevents the Institute from exercising it to acquire additional shares of common stock if its beneficial ownership of Company common stock would exceed 9.99% immediately after the exercise. On October 29, 2024, the Company waived the beneficial ownership blocker contained in the Pre-Funded Warrants, and on October 29, 2024, the Institute exercised all of its Pre-Funded Warrants to acquire 235,000 shares of Company common stock for an aggregate purchase price of $23.50. On December 31, 2024, the Institute transferred an aggregate of 450,000 Series J Warrants to its trustee and certain donor advisors as compensation for prior services. As trustee of the Institute, Casey A. Jenkins received 150,000 of the Series J Warrants transferred. All acquisitions described in Item 3 above and Item 5 below were for investment purposes. The reporting persons may make additional open market purchases or sales or engage in estate planning or other transactions in Company common stock, from time to time. The transfers of the Series J Warrants describe in Item 3 above were made as compensation for prior services provided. The reporting persons have no present intent to take any action that would result in: (a) the acquisition by any person of additional securities of the Company or the disposition of securities of the Company; (b) an extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Company or any subsidiary thereof; (c) a sale or transfer of a material amount of assets of the Company or any subsidiary thereof; (d) any change in the present board of directors or management of the Company, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board; (e) any material change in the present capitalization or dividend policy of the Company; (f) any other material change in the Company's business or corporate structure; (g) any changes in the Company's charter, bylaws, or instruments corresponding thereto, or other actions which may impede the acquisition of control of the Company by any person; (h) causing a class of securities of the Company to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association; (i) a class of equity securities of the Company becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Securities Exchange Act of 1934, as amended; or (j) any action similar to any of those enumerated above. See the cover pages to this Amendment. See the cover pages to this Amendment. The following transactions were effected by the reporting persons within 60 days prior to the date hereof: See Item 3 above. There were no other transactions in Company common stock effected by the reporting persons within 60 days of the date hereof. None Not applicable See Item 3 above. The waiver of the beneficial ownership blocker contained in the Pre-Funded Warrants was effected pursuant to a Waiver Agreement dated October 29, 2024. There are no other contracts, arrangements, understandings, or relationships with respect to any securities of the Company, including but not limited to transfer or voting of any of such securities, finder's fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or loss or the giving or withholding of proxies. 1.1 Underwriting Agreement dated as of August 30, 2024, by and between Catheter Precision, Inc. and Ladenburg Thalmann & Co. Inc., as Representative of the Underwriters (incorporated by reference to Exhibit 1.1 of Company's Report on Form 8-K filed on September 6, 2024, 2024 (File No. 001-38677)) - https://www.sec.gov/Archives/edgar/data/1716621/000165495424011589/rmed_ex11.htm 4.1 Form of Series H Warrant (incorporated by reference to Exhibit 4.1 of Company's Report on Form 8-K filed on September 6, 2024, 2024 (File No. 001-38677)) - https://www.sec.gov/Archives/edgar/data/1716621/000165495424011589/rmed_ex41.htm 4.2 Form of Series I Warrant (incorporated by reference to Exhibit 4.2 of Company's Report on Form 8-K filed on September 6, 2024, 2024 (File No. 001-38677)) - https://www.sec.gov/Archives/edgar/data/1716621/000165495424011589/rmed_ex42.htm 4.3 Form of Series J Warrant (incorporated by reference to Exhibit 4.3 of Company's Report on Form 8-K filed on September 6, 2024, 2024 (File No. 001-38677)) - https://www.sec.gov/Archives/edgar/data/1716621/000165495424011589/rmed_ex43.htm 4.4 Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.4 of Company's Report on Form 8-K filed on September 6, 2024, 2024 (File No. 001-38677)) - https://www.sec.gov/Archives/edgar/data/1716621/000165495424011589/rmed_ex44.htm 4.5 Waiver Agreement dated October 29, 2024 (incorporated by reference to Exhibit 10.1 of Company's Report on Form 8-K filed on October 30, 2024, 2024 (File No. 001-38677)) - https://www.sec.gov/Archives/edgar/data/1716621/000165495424013502/catheter_ex101.htm 99 Exhibit A Jenkins Casey A. /s/ Casey A. Jenkins Casey A. Jenkins 01/03/2025 Jenkins Family Charitable Institute /s/ Casey A. Jenkins Casey A. Jenkins, Trustee 01/03/2025